3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
44
Specimen Handling
38
enzalutamide
30
Nivolumab
30
pembrolizumab
28
Docetaxel
23
Gemcitabine
22
apalutamide
20
Prednisone
20
Biopsy
20
Abiraterone Acetate
18
Androgen Antagonists
17
cabozantinib
14
darolutamide
13
abiraterone
13
Radiotherapy
13
Cisplatin
12
enfortumab vedotin
11
Radiation
11
Ipilimumab
11
Pluvicto
10
erdafitinib
9
belzutifan
9
atezolizumab
9
X-Rays
9
Radiosurgery
9
Mitomycin
9
olaparib
8
cabazitaxel
8
Standard of Care
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Genetic Counseling
×
Genitourinary
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled